Shire looks (far) East

Shire Pharmaceuticals Group plc is looking to build in the Pacific Rim and continental Europe to maintain its revenue and profits growth. Speaking after the company announced year-on-year revenue growth of 25 percent at $119 million for the first quarter, CEO Rolf Stahel told BioCentury that he will establish distributorships through most of the Asia Pacific region but wants to lay down a corporate presence in Japan.

Shire (LSE:SHP; SHPGY, Andover, U.K.) derives only $4.8 million of its revenues from sales outside the U.S., the U.K. and Ireland.